One of the EUnetHTA JA2 specific objectives was “to test the capacity of the national HTA bodies to jointly produce structured core HTA information and to apply it in national context”

A primary target group for EUnetHTA JA2 was the producers of HTA. Whereas, the feasibility of the cross-border collaboration in the projects of common interest was proven by production of three full core HTAs and 12 rapid REAs, the usefulness of the joint assessments was indicated by the EUnetHTA partners by adaptation of the produced information to the national or regional level. Please see an overview of the national uptake activities here.

The growing potential of this joint production to deliver value to the healthcare systems was also gradually acknowledged by the industry, especially pharmaceutical companies. This acknowledgement was manifested in the increasingly more visible and active participation of pharmaceutical and medical technology companies in the process (i.e. expressions of interest and scoping meetings) in the second half of JA2. 

Focusing on the main JA2 objectives, EUnetHTA provided a structured opportunity to test the capacity of national HTA institutions to cooperate in specific assessments (including rapid REAs) within a network structure and address the issues of utilisation of jointly produced structured HTA information in the development of local reports. A direct application of joint assessment reports in local decision making, e.g., on reimbursement of health technologies, should be done with caution and after a thorough check of transferability of the joint work results in relation to the local context and needs. Nonetheless, it is worth noting that already in JA2 a number of cases of direct use of the joint assessments into making local decisions on reimbursement was reported.